These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9531339)

  • 1. Serum erythropoietin concentration in anaemia of visceral leishmaniasis (kala-azar) before and during antimonial therapy.
    Saeed AM; Khalil EA; Elhassan AM; Hashim FA; Elhassan AM; Fandrey J; Jelkmann W
    Br J Haematol; 1998 Mar; 100(4):720-4. PubMed ID: 9531339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A thirty day course of sodium stibogluconate for treatment of Kala-azar in Nepal.
    Karki P; Koirala S; Parija SC; Hansdak SG; Das ML
    Southeast Asian J Trop Med Public Health; 1998 Mar; 29(1):154-8. PubMed ID: 9740292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of sodium stibogluconate and rifampicin in post kala-azar dermal leishmaniasis.
    Sharma VK; Prasad HR; Sethuraman G; Khaitan BK
    Indian J Dermatol Venereol Leprol; 2007; 73(1):53-4. PubMed ID: 17314452
    [No Abstract]   [Full Text] [Related]  

  • 4. Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis).
    Thakur CP
    Trans R Soc Trop Med Hyg; 1984; 78(3):391-8. PubMed ID: 6087515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketoconazole in antimonial unresponsive cases of Kala-azar.
    Jha TK; Singh NK; Jha S
    J Assoc Physicians India; 1995 May; 43(5):347. PubMed ID: 9081966
    [No Abstract]   [Full Text] [Related]  

  • 6. Post kala-azar ocular leishmaniasis.
    el Hassan AM; Khalil EA; el Sheikh EA; Zijlstra EE; Osman A; Ibrahim ME
    Trans R Soc Trop Med Hyg; 1998; 92(2):177-9. PubMed ID: 9764325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis.
    Zijlstra EE; Khalil EA; Kager PA; El-Hassan AM
    Br J Dermatol; 2000 Jul; 143(1):136-43. PubMed ID: 10886148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Observations on the effect of verapamil with sodium stibogluconate in kala azar.
    Thakur CP; Kumar M
    Trop Geogr Med; 1992 Jan; 44(1-2):15-8. PubMed ID: 1323160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.
    Ritmeijer K; Veeken H; Melaku Y; Leal G; Amsalu R; Seaman J; Davidson RN
    Trans R Soc Trop Med Hyg; 2001; 95(6):668-72. PubMed ID: 11816442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya.
    Moore E; O'Flaherty D; Heuvelmans H; Seaman J; Veeken H; de Wit S; Davidson RN
    Bull World Health Organ; 2001; 79(5):388-93. PubMed ID: 11417033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India.
    Thakur CP; Olliaro P; Gothoskar S; Bhowmick S; Choudhury BK; Prasad S; Kumar M; Verma BB
    Trans R Soc Trop Med Hyg; 1992; 86(6):615-6. PubMed ID: 1337634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan.
    Veeken H; Ritmeijer K; Seaman J; Davidson R
    Trop Med Int Health; 2000 May; 5(5):312-7. PubMed ID: 10886792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alteration of serum copper in Kala-azar patients during SAG therapy.
    Banerjee M; Rahman M; Shamuzzaman AK; Akhter S; Deb K
    Mymensingh Med J; 2007 Jan; 16(1):89-93. PubMed ID: 17344788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The response of Kenyan kala-azar to treatment with sodium stibogluconate.
    Rees PH; Kager PA; Wellde BT; Hockmeyer WT
    Am J Trop Med Hyg; 1984 May; 33(3):357-61. PubMed ID: 6329010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
    Atia AM; Mumina A; Tayler-Smith K; Boulle P; Alcoba G; Elhag MS; Alnour M; Shah S; Chappuis F; van Griensven J; Zachariah R
    Trop Med Int Health; 2015 Dec; 20(12):1674-84. PubMed ID: 26427033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
    Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
    Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases.
    Thakur CP; Sinha GP; Pandey AK; Kumar N; Kumar P; Hassan SM; Narain S; Roy RK
    Ann Trop Med Parasitol; 1998 Jul; 92(5):561-9. PubMed ID: 9797829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PCR for diagnosis and assessment of cure in kala-azar patients in Bangladesh.
    Salam MA; Mondal D; Kabir M; Ekram AR; Haque R
    Acta Trop; 2010 Jan; 113(1):52-5. PubMed ID: 19769932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and laboratory study of kala-azar in children in Nepal.
    Singh K; Singh R; Parija SC; Faridi MM; Bhatta N
    J Trop Pediatr; 1999 Apr; 45(2):95-7. PubMed ID: 10341503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-kala-azar dermal leishmaniasis with visceral leishmaniasis: a rare presentation.
    Rijal A; Agrawal S; Agarwalla A; Agrawal A; Rijal S
    Int J Dermatol; 2005 Jun; 44(6):494-6. PubMed ID: 15941439
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.